Abstract 71P
Background
Sint has been used to treat patients (pts) with advanced NSCLC. This observational study aims to describe the real-world use of Sint and to explore its real-world effectiveness in the first-line (1L) treatment of advanced NSCLC.
Methods
Pts with advanced NSCLC initiating 1L therapy with Sint between Aug 1st 2018 and Aug 1st 2020 in 4 tertiary hospitals in mainland China were included. Data in demographic and clinical characteristics, treatment patterns and outcomes were retrospectively collected through medical records. Descriptive analysis was used to describe the baseline characteristics and treatment patterns. Kaplan-Meier method was used to calculate the median progression-free survival (mPFS).
Results
102 pts (85.3% men) were included with mean age of 63.9±9.5 years (median follow-up time: 4.8 months (mo) (range 0.0-32.0)). The most commonly-used treatment regimen was Sint + platinum (Pt) + taxanes (56.0%) for squamous NSCLC (sqNSCLC) and Sint + Pt + pemetrexed (38.5%) for non-squamous NSCLC (nsqNSCLC) (Table). The mPFS was 15.8 mo (95% CI: 11.5-NA) and 12.0 mo (95% CI: 6.3-NA) respectively for sqNSCLC and nsqNSCLC pts. The mPFS was 17.0 mo (95% CI 11.5-NA) in sqNSCLC pts using Sint + Pt + taxanes as 1L therapy and 7.2 mo (95% CI: 0.7-NA) in nsqNSCLC pts. The ORR was 57.1% and 53.6% respectively for sqNSCLC and nsqNSCLC pts. Table: 71P
Baseline characteristics and treatment pattern of NSCLC
| Total (N=102) | sqNSCLC (N=50) | nsqNSCLC (N=52) | |
| Age (mean±SD), years | 63.9±9.5 | 64.9±7.0 | 63.0±11.4 |
| Male (%) | 85.3 | 88.0 | 82.7 |
| Stage at first diagnosis (%) | |||
| III | 21.6 | 34.0 | 9.6 |
| IV | 42.2 | 28.0 | 55.8 |
| Median of Sint cycle number | 4.0 | 3.0 | 5.0 |
| Treatment pattern (%) | |||
| Sint monotherapy | 6.9 | 4.0 | 9.6 |
| Sint + Pt + taxanes | 36.3 | 56.0 | 17.3 |
| Sint + Pt + pemetrexed | 19.6 | 0.0 | 38.5 |
| Sint + Pt + gemcitabine | 5.9 | 12.0 | 0.0 |
| Sint + Pt + anti-VEGF therapy + pemetrexed | 5.9 | 0.0 | 11.5 |
| Sint + others | 25.5 | 28.0 | 23.1 |
Conclusions
For sqNSCLC pts with Sint as 1L therapy, taxanes and gemcitabine are more preferred, while for nsqNSCLC pts, pemetrexed is more often combined. The real-world effectiveness of 1L treatment of Sint for advanced NSCLC pts is promising from the study.
Legal entity responsible for the study
Eli Lilly China.
Funding
Lilly (Shanghai) Management Co., Ltd.
Disclosure
L. Zhang: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. L. Liu: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. J. Li: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. W. Ding: Financial Interests, Institutional, Advisory Role, received Lilly’s sponsorship: Happy Life Technology. All other authors have declared no conflicts of interest.